Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

A mere $20 stock of Gilead in 2011 saw a considerable momentum in the years ... as investors could look forward to impressive ...

TD Cowen raised the firm’s price target on Gilead (GILD) to $95 from $85 and keeps a Buy rating on the shares. The firm updated its model ...

Maxim downgraded Gilead (GILD) to Hold from Buy. The stock has appreciated significantly following a pullback in the first half of the year, ...

Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

Xavier Lorenzo / Investopedia Many people invest in dividend-bearing mutual funds to generate additional income. While this can be simple and effective in increasing your regular earnings ...

Gilead is a top HIV treatment company ... which pays 3.2% per year in dividends. It's the most expensive stock on this list, trading at a forward P/E of 14. But even that is still incredibly ...

In an investing world where you can pick from dozens of different strategies and methodologies for generating returns, dividend investing remains one of the best ways to accumulate wealth over the ...